Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR

Victor H. Villar\textsuperscript{a,b,c}, Tra Ly Nguyen\textsuperscript{a,b,c}, Silvia Terés\textsuperscript{a,b,c}, Clément Bodineau\textsuperscript{a,b,c}, and Raúl V. Durán\textsuperscript{a,b,c}

\textsuperscript{a}Institut Européen de Chimie et Biologie, Pessac, France; \textsuperscript{b}Institut Bergonié, ACTION Unit U1218 INSERM, Bordeaux, France; \textsuperscript{c}University of Bordeaux, Bordeaux, France

\textbf{ABSTRACT}

A master promoter of cell growth, mammalian target of rapamycin (mTOR) is upregulated in a large percentage of cancer cells. Still, targeting mTOR using rapamycin has a limited outcome in patients. Our recent results highlight the additional role of mTOR as a tumor suppressor, explaining these modest results in the clinic.

The serine/threonine kinase mammalian target of rapamycin (mTOR) is a central regulator of mammalian cell growth. mTOR forms 2 complexes, termed mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). While both complexes are stimulated by growth factors, only mTORC1 can be activated by amino acids (\textsuperscript{1}Cell Res). Particularly, the catabolism of glutamine (glutaminolysis), which yields \(\alpha\)-ketoglutarate (\(\alpha\)KG), activates the lysosomal translocation and subsequent activation of mTORC1 (\(\alpha\)Mol Cell). Recently, our work revealed an unexpected mechanism by which the unbalanced activation of glutaminolysis in the absence of other amino acids induces a particular type of mTORC1-dependent cell death that we are naming “glutamoptosis” (\textsuperscript{2}Nat Comm). During glutamoptosis, abnormally high levels of glutaminolytic \(\alpha\)KG during nutrient restriction activates mTORC1, which in turn inhibits autophagy (\textsuperscript{4}Autophagy). The inhibition of autophagy during glutamoptosis results in the accumulation of the autophagic protein sequestosome 1 (SQSTM1/p62), as SQSTM1/p62 is degraded during autophagy (\textsuperscript{2}Cell). Our results showed that the increasing levels of SQSTM1/p62 in these restrictive conditions induce its interaction with caspase 8 to trigger apoptosis. The inhibition of mTORC1 reactivates autophagy and decreases SQSTM1/p62 levels, abrogating the induction of apoptosis by glutaminolysis. Thus, surprisingly, the inhibition of mTORC1 prevents glutamoptosis-mediated cell death, representing a tumor suppressor function of mTORC1 during nutritional imbalance.

For a long time, mTORC1 is known to be hyperactive in a large variety of different types of human cancer (\textsuperscript{2}Cell). Therefore, this pathway has been considered as a major target for cancer therapy. However, for unclear reasons, the inhibition of mTORC1 as a therapeutic strategy has only modestly improved the outcome of patients (\textsuperscript{2}N Engl J Med). Several reasons have been invoked to explain this lack of success in the use of rapamycin and analogues (rapalogues) in the clinic. The most accepted reason is the existence of a negative feedback loop downstream of mTORC1 which, upon its inhibition, upregulates the phosphoinositide 3-kinase (PI3K) signaling (\textsuperscript{4}Curr Biol). The upregulation of the PI3K pathway would result in a deleterious effect of rapamycin treatment, as it promotes cancer growth, including the activation of mTORC2. To overcome this issue, dual inhibitors targeting both mTOR complexes have been designed, although it is unclear that they can actually improve the outcome of rapamycin in patients.

Our recent results suggest that additional fundamental reasons might explain the capacity of cancer cells to escape rapamycin treatment. As explained above, the inhibition of mTORC1 or the dual inhibition of both mTORC1 and mTORC2 during nutritional imbalance prevents glutamoptosis and promotes cell survival. Considering the restrictive nature of tumors (particularly solid tumors) due to their abnormal vasculature, and their general avidity to consume glutamine, tumors might constitute favorable microenvironments to induce glutamoptosis. In these conditions, the inhibition of mTORC1 during cancer therapy would prevent tumor growth, but at the same time would provide with an opportunity to cancer cells to avoid cell death. In other words, rapamycin treatment will result in a merely cytostatic effect, sustaining the survival of tumor cells. Upon treatment discontinuation, tumors will resume their growth. As a result, cancer progression will be only delayed during the period of rapamycin treatment or until the acquisition of rapamycin resistance mechanism by the cytostatic tumor cell.

These tumor suppressor functions of mTORC1 highlight the complexity of the action mechanisms of central cell growth regulators, such as mTOR, and how microenvironmental cues influence their function (Fig. 1). The assumption that the inhibition of these cell growth regulators will inevitably result in
In conclusion, the tumor suppressor function of mTORC1 during nutritional imbalance points at the necessity of finding alternatives to improve the outcome of mTORC1 inhibition in the clinics and questions the pertinence of the use of rapamycin as monotherapy in cancer patients.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

This work was supported by funds from the following institutions: Institut National de la Santé et de la Recherche Médicale - INSERM, Fondation pour la Recherche Médicale, Conseil Régional d’Aquitaine, Fondation ARC pour la Recherche sur le Cancer, SIRIC-BRIO, and Institut Européen de Chimie et Biologie.

References

1. Shimobayashi M, Hall MN. Multiple amino acid sensing inputs to mTORC1. Cell Res 2016; 26:7-20; PMID:26658722; https://doi.org/10.1038/cr.2015.146
2. Durán RV, Oppliger W, Robitaille AM, Heisrich L, Skendaj R, Gottlieb E, Hall MN. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47:349-58; PMID:22749528; https://doi.org/10.1016/j.molcel.2012.05.043
3. Villar VH, Nguyen TL, Delcroix V, Terés S, Bouchecareilh M, Salin B, Bodineau C, Vacher P, Priault M, Soubeyran P, et al. mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nature Comm 2017; 8:14124; https://doi.org/10.1038/ncomms14124
4. Villar VH, Merhi F, Djavaheri-Mergny M, Durán RV. Glutaminolysis and autophagy in cancer. Autophagy 2015; 11:1198-208; PMID:26054373; https://doi.org/10.1080/15548627.2015.1053680
5. Moscat J, Karin M, Diaz-Meco MT. p62 in Cancer: Signaling Adaptor Beyond Autophagy. Cell 2016; 167:606-9; PMID:27768885; https://doi.org/10.1016/j.cell.2016.09.030
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cell 2007; 129:9-22; PMID:17613433; https://doi.org/10.1016/j.cell.2007.05.008
7. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawski E, Sosman J, McDermott D, Budrog I, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81; PMID:17538086; https://doi.org/10.1056/NEJMoa066838
8. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14:1650-6; PMID:15380067; https://doi.org/10.1016/j.cub.2004.08.026
9. Rangwala R, Chang YC, Hu J, Algary KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1391-402; PMID:24991838; https://doi.org/10.4161/auto.29119
10. Tennant DA, Frezza C, MacKenzie ED, Nguyen QD, Zheng L, Selak MA, Roberts DL, Dive C, Watson DG, Abougry EO, et al. Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene 2009; 28:4009-21; PMID:19718054; https://doi.org/10.1038/onc.2009.250